MENLO PARK, Calif., March 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.
HAYWARD, Calif., March 28, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering.
CHICAGO, March 28, 2024--Equity Commonwealth (NYSE: EQC) announced today that the company will release its first quarter 2024 operating results on Wednesday, May 1, 2024, after the close of trading. A conference call to discuss those results will be held on Thursday, May 2, 2024, at 9:00 am Central Time. The conference call will be available via live audio webcast on the Investor Relations section of the company’s website (www.eqcre.com). A replay of the audio webcast will also be available foll
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|
Símbolo | Último precio | Cambio | Cambio de % |
---|---|---|---|